The arrival of OpenAI's DALL-E 2 in the spring of 2022 marked a turning point in AI, when text-to-image generation suddenly ...

Just today, Amgen (AMGN) announced updated Uplizna results showing a deepening of responses six months after a single repeat infusion, Opco points out. It believes extrapolating from Cartesian’s ...

This guide covers all the logo design rules, best practices, tips, examples, and more to equip you with the knowledge for crafting brilliant logos. Logos are one of the most vital elements of any ...

From its origins in a garage to becoming one of the most recognisable symbols in the world, explore the story behind the iconic Apple logo design. Apple is a company that has changed the technology ...

Amgen Inc.'s stock has surged 13% recently, likely due to promising developments with its obesity injection, MariTide, which offers unique benefits over current treatments. MariTide's dual ...

Dow Jones member Verizon is climbing despite the overall market correction. Amgen's weight loss drug is helping it to outperform the broad market. The NASDAQ opened more than 2% lower on Monday ...

Amgen and Kyowa Kirin’s anti-OX40 antibody rocatinlimab vindicated itself this weekend, with new Phase III data pointing to its strong efficacy in moderate to severe atopic dermatitis. These findings ...

The Secret Service shot a man near the White House on Sunday shortly after midnight after an “armed confrontation” with law enforcement, according to the agency. The encounter happened near ...

Amgen and CytomX Therapeutics have kicked a phase 1 T-cell engager to the curb, axing the asset after assessing the clinical data and their pipeline priorities. CytomX signaled the EGFRxCD3 ...

Phase 3 studies for Amgen’s closely watched obesity drug were posted on a federal database. Elsewhere, Novo started up an online pharmacy and a base editing therapy for Duchenne advanced. Today, a ...

32,404 people played the daily Crossword recently. Can you solve it faster than others?32,404 people played the daily Crossword recently. Can you solve it faster than others?

Amgen (NASDAQ:AMGN) has announced the beginning of two Phase 3 studies for its weight loss candidate MariTide as the company aims to take a slice of a burgeoning obesity drug market dominated by ...